Pegvaliase

From WikiMD.org
Jump to navigation Jump to search

Pegvaliase

Pegvaliase (pronunciation: peg-VAL-i-ase) is a medication used in the treatment of phenylketonuria, a rare genetic disorder. It is marketed under the brand name Palynziq by BioMarin Pharmaceutical.

Etymology

The name "Pegvaliase" is derived from the medication's composition. "Peg" refers to polyethylene glycol, a component used to increase the medication's half-life in the body. "Valiase" is a reference to the enzyme phenylalanine ammonia lyase (PAL), which the medication is designed to replace in patients with phenylketonuria.

Usage

Pegvaliase is used to lower blood phenylalanine levels in adults with phenylketonuria who have uncontrolled blood phenylalanine levels on current treatment. It works by helping the body break down phenylalanine.

Related Terms

  • Phenylketonuria: A rare genetic disorder in which the body can't process the amino acid phenylalanine.
  • Phenylalanine: An essential amino acid that is not produced by the body and must be obtained from the diet.
  • Phenylalanine ammonia lyase (PAL): An enzyme that breaks down phenylalanine in the body.
  • Polyethylene glycol (PEG): A component used in many medications to increase their half-life in the body.

See Also

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski